Topical Myristyl Nicotinate Cream on the Skin of Healthy Volunteers

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
University of Arizona Identifier:
First received: February 19, 2008
Last updated: September 28, 2010
Last verified: September 2010

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of topical myristyl nicotinate cream may stop skin cancer from forming.

PURPOSE: This randomized phase I trial is studying the side effects and best way to give topical myristyl nicotinate cream on the skin of healthy volunteers.

Condition Intervention Phase
Healthy, no Evidence of Disease
Non-melanomatous Skin Cancer
Drug: topical myristyl nicotinate cream
Other: placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Phase I Study of Topical Myristyl Nicotinate Cream on Human Skin in Healthy Volunteers

Resource links provided by NLM:

Further study details as provided by University of Arizona:

Primary Outcome Measures:
  • Safety of myristyl nicotinate at the administered doses [ Designated as safety issue: Yes ]

Enrollment: 22
Study Start Date: August 2007
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I
Participants apply topical myristyl nicotinate to one forearm and topical placebo to the other forearm once daily for 4 weeks.
Drug: topical myristyl nicotinate cream
Applied topically
Other: placebo
Applied topically
Experimental: Arm II
Participants receive treatment as in arm I but on opposite forearms.
Drug: topical myristyl nicotinate cream
Applied topically
Other: placebo
Applied topically

Detailed Description:


  • To determine if topical myristyl nicotinate (MN) is a safe, tolerable treatment in healthy volunteers.
  • To determine if topically administered MN cream is associated with any significant local or systemic toxicity in normal human subjects in a one-month period.

OUTLINE: Participants are randomized to 1 of 2 treatment arms and serve as their own controls.

  • Arm I: Participants apply topical myristyl nicotinate to one forearm and topical placebo to the other forearm once daily for 4 weeks.
  • Arm II: Participants receive treatment as in arm I but on opposite forearms. All participants undergo blood collection for chemistry analysis (SMA-20 and CBC) at baseline and at 2 and 4 weeks.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes


  • Healthy volunteers who have not used topical medications to the skin of the upper extremities, except for emollients or sunscreens, for at least 30 days prior to study entry


  • Must agree to limit sun exposure as much as possible and wear protective clothing on the forearms in place of using sunscreens or moisturizers
  • Female participants must be surgically sterile by hysterectomy or post menopausal for at least 1 year
  • No signs of inflammation or irritation of the skin on the forearms
  • No prior history of actinic keratosis or skin cancer on the forearm
  • No known immunosuppression by virtue of medication or disease, including AIDS patients
  • No uncontrolled intercurrent illness including, but not limited to any of the following:

    • Ongoing or active infection
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • Cardiac arrhythmia
  • No psychiatric illness/social situations that would limit compliance with study requirements
  • No invasive cancer within the past 5 years
  • No skin conditions felt by the study physician to contraindicate enrollment including, but not limited to, psoriasis or atopic dermatitis within a proposed treatment area


  • See Disease Characteristics
  • No concurrent therapy (e.g., retinoids, fluorouracil) on the forearms that may interfere with clinical evaluations
  • More than 30 days since prior and no concurrent or planned participation in another clinical trial
  • No concurrent oral supplemental niacin, by itself or in the form of a multi-vitamin that exceeds 40 mg/day
  • No concurrent oral prednisone
  • No concurrent immunosuppressants/immunomodulators (e.g., cyclosporine, chemotherapeutic agents, or biologic therapy)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00619060

United States, Arizona
Arizona Cancer Center at University of Arizona Health Sciences Center
Tucson, Arizona, United States, 85724-5024
Sponsors and Collaborators
University of Arizona
National Cancer Institute (NCI)
Study Chair: Clara Curiel, MD University of Arizona
  More Information

Additional Information:
No publications provided

Responsible Party: Clara Curiel, M.D., Arizona Cancer Center at University of Arizona Health Science Center Identifier: NCT00619060     History of Changes
Other Study ID Numbers: CDR0000582627  P30CA023074  UARIZ-BIO-07-085 
Study First Received: February 19, 2008
Last Updated: September 28, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Arizona:
skin cancer
healthy, no evidence of disease

Additional relevant MeSH terms:
Skin Neoplasms
Neoplasms by Site
Skin Diseases
Nicotinic Acids
Cardiovascular Agents
Growth Substances
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Vasodilator Agents
Vitamin B Complex
Vitamins processed this record on February 08, 2016